Belgium-based biopharmaceutical firm ThromboGenics has announced that its partner Alcon has launched Jetrea (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion (VMA) in Canada. According to the company, Canada is the ...
Tags: Alcon, Vitreomacular Adhesion
Integrated biopharmaceutical company ThromboGenics has obtained Health Canada approval for Jetrea (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion (VMA). Launch of the drug in Canada will be conducted by Alcon, ...
Integrated biopharmaceutical company ThromboGenics has announced the launch of Jetrea in Denmark and Sweden by Alcon, a division of Novartis. Alcon expects to roll out the European Commission approved Jetrea, which is indicated for the ...
The US FDA has accepted ThromboGenics'biologics license application for ocriplasmin intravitreal injection,2.5mg/ml and granted it priority review. The company proposed the injection for the treatment of symptomatic Vitreomacular ...
The USFDA has approved ThromboGenics'Jetrea(ocriplasmin)for the treatment of symptomatic vitreomacular adhesion(VMA). The approval was based on the Phase III trial data which demonstrated that Jetrea is superior to placebo for the ...
Tags: ThromboGenics'Jetrea, symptomatic vitreomacular adhesion, USFDA